Catalyst Dossier · compiled by CeliA 🧫
AstraZeneca PLC (AZN)
Pharmaceutical Preparations · market cap $273.6B · as of 2026-07-13
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-12-10 (est.)
Phase 2
Pipeline
20
programs
Upcoming events
8
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
AstraZeneca PLC (AZN) is a large-cap Swedish-British pharmaceutical and biotech company headquartered in Cambridge, UK, with ~89,900 employees and a market cap of approximately $273.6B. The company operates a broad, multi-franchise pipeline spanning oncology, respiratory, cardiovascular, and metabolic disease, with lead pipeline asset AZD1152 in Phase 3 for Acute Myeloid Leukemia and a high-importance Phase 3 catalyst in Capivasertib (ovarian cancer) expected in late October 2026. Recent trial readouts have been mixed, with two negative outcomes in early July 2026 offset by several positive Phase 2 and Phase 3 data points.
The catalyst path
- 2026-12-10 (est.)Phase 2 · Baxdrostat/dapagliflozinimp 7/10
- 2027-01-04 (est.)Phase 3 · AZD0780imp 9/10
- 2027-01-04 (est.)Phase 2 · AZD0780imp 7/10
- 2027-01-29 (est.)Phase 3 · Casdatifanimp 9/10
- 2027-01-29 (est.)Phase 2 · AZD9550imp 7/10
- 2027-02-18 (est.)Phase 3 · Zibotentan/Dapagliflozinimp 9/10
- 2027-02-23 (est.)Phase 3 · Anifrolumabimp 9/10
- 2027-03-31 (est.)Phase 2 · AZD4360imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| AZD1152 | Phase 3 | Acute Myeloid Leukemia |
| AC2993 (exenatide) | Phase 2 | Diabetes Mellitus |
| AZD6234 | Phase 2 | Obesity/Overweight |
| MEDI6570 | Phase 2 | Coronary Heart Disease (CHD) |
| Tremelimumab monotherapy | Phase 2 | Urothelial Bladder Cancer |
| B - Exenatide 10 mcg twice daily | Phase 2 | Diabetes Mellitus, Type 2 |
| ZD1839 | Phase 2 | Mesothelioma |
| Chemotherapy | Phase 3 | Anticancer Treatment |
| Saruparib (AZD5305) | Phase 3 | Ovarian Cancer |
| Ticagrelor Dose 1a + Dose 2a | Phase 2 | Investigation of Platelet Aggregation in Paediatric Patients With Sickle Cell Disease |
| exenatide twice daily | Phase 3 | Type 2 Diabetes Mellitus |
| Ciclesonide nasal | Phase 3 | Rhinitis, Allergic, Perennial |
| SBC-103 | Phase 2 | Mucopolysaccharidosis IIIB |
| fostamatinib | Phase 3 | Rheumatoid Arthritis |
| AZD3470 | Phase 2 | Lymphoma |
| Benralizumab Arm B | Phase 3 | Moderate to Very Severe Chronic Obstructive Pulmonary Disease |
| D961H capsule 10mg | Phase 3 | Reflux Esophagitis |
| AZD1940 | Phase 2 | Pain |
| ZD9393 (Zoladex) 10.8 mg | Phase 3 | Breast Cancer |
| AZD9793 Intravenous (IV) monotherapy | Phase 2 | Hepatocellular Carcinoma |
Price & technical context
3-month
-4.7%
6-month
-8.4%
12-month
+10.2%
52-wk range
$92.72–$209.48
vs 50-day MA
+2.4%
vs 200-day MA
-8.1%
Realized vol
85.7%
Max drawdown
-61.4%
Daily closes through 2026-09-21. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for AZN (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.